Promoter methylation and expression levels of selected hematopoietic genes in pediatric B-cell acute lymphoblastic leukemia.
- Author:
Ewa MUSIALIK
1
;
Mateusz BUJKO
;
Paulina KOBER
;
Agnieszka WYPYCH
;
Karolina GAWLE-KRAWCZYK
;
Michal MATYSIAK
;
Janusz Aleksander SIEDLECKI
Author Information
- Publication Type:Original Article
- Keywords: DNA methylation; Acute lymphoblastic leukemia; Gene expression; Transcription factors
- MeSH: B-Lymphocytes*; Child; Classification; DNA; DNA Methylation; Epigenomics; Gene Expression; Genes, Homeobox; Humans; Interferon Regulatory Factors; Leukocytes; Methylation*; National Cancer Institute (U.S.); Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma*; Precursor Cells, B-Lymphoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Sodium; Transcription Factors
- From:Blood Research 2015;50(1):26-32
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Precursor B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common neoplasm in children and is characterized by genetic and epigenetic aberrations in hematopoietic transcription factor (TF) genes. This study evaluated promoter DNA methylation and aberrant expression levels of early- and late-acting hematopoietic TF genes homeobox A4 and A5 (HOXA4 and HOXA5), Meis homeobox 1 (MEIS1), T-cell acute lymphocytic leukemia 1 (TAL1), and interferon regulatory factors 4 and 8 (IRF4 and IRF8) in pediatric B-cell ALL. METHODS: Blood samples of 38 ALL patients and 20 controls were obtained. DNA was treated with sodium bisulfite and DNA methylation level of HOXA4, HOXA5, MEIS1, TAL1, IRF4, and IRF8 was assessed using quantitative methylation-specific polymerase chain reaction (PCR). Relative gene expression was measured using quantitative reverse transcription-PCR. RESULTS: Aberrant methylation of TAL1, IRF8, MEIS1, and IRF4 was observed in 26.3%, 7.9%, 5.3%, and 2.6% patients, respectively, but not in controls. HOXA4 and HOXA5 were methylated in some controls and hypermethylated in 16% and 5% patients, respectively. IRF8, MEIS1, and TAL1 expression was lower in patients than in controls. MEIS1 expression was inversely correlated with white blood cell (WBC) count. HOXA4 expression was down-regulated in patients with high risk according to the National Cancer Institute (NCI) classification. TAL1 methylation was slightly elevated in patients aged >9 years and in patients showing relapse, suggesting its potential prognostic value. CONCLUSION: Aberrant methylation and expression of the selected hematopoietic genes were correlated with demographic/clinical prognostic factors of pediatric ALL, such as age, WBC count, and NCI risk classification.
